Trinity Biotech
TRIB
95 hedge funds and large institutions have $260M invested in Trinity Biotech in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 41 increasing their positions, 32 reducing their positions, and 9 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 32
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
2% more funds holding
Funds holding: 93 → 95 (+2)
18% less capital invested
Capital invested by funds: $318M → $260M (-$58.3M)
24% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$4.5M |
| 2 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$3.34M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.94M |
| 4 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
+$2.68M |
| 5 |
PIM
Paradice Investment Management
Denver,
Colorado
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.3M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.53M |
| 3 |
VAM
Visium Asset Management
New York
|
-$3.46M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$2.51M |
| 5 |
TCM
Tygh Capital Management
Portland,
Oregon
|
-$1.33M |
TRIB Hedge Fund Activity: Q3 2014 in Review
95 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2014, worth a combined $260M — down 18% from $318M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TRIB positions and 9 closed out — a net gain of 2 holders — while 41 added to existing stakes and 32 trimmed.
The largest buyer was Northern Trust, adding an estimated $4.5M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.3M sold.
- 95 institutional investors held Trinity Biotech (TRIB) as of Q3 2014, up from 93 in Q2 2014.
- Funds reported $260M of Trinity Biotech stock for Q3 2014, down 18% quarter-over-quarter.
- 11 funds opened new Trinity Biotech positions in Q3 2014 and 9 closed out, a net change of +2 holders.
- The largest Trinity Biotech buyer in Q3 2014 was Northern Trust, an estimated $4.5M added.
- The largest Trinity Biotech seller in Q3 2014 was Fidelity Investments, an estimated $9.3M sold.
Based on aggregated 13F filings for Q3 2014.